No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease
Date
2001
Authors
Van Rensburg C.J.
Bardhan K.D.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Objective Although a proton pump inhibitor (PPI) and a prokinetic drug are often combined for the medical treatment of gastro-oesophageal reflux disease (GORD), there are few well-conducted clinical studies on the efficacy and tolerability of this therapy. This study investigates whether pantoprazole plus cisapride leads to an additional benefit in comparison to pantoprazole alone. Design and setting Randomized double-blind prospective multicentre study conducted in patients of 33 hospitals in Ireland, South Africa and the UK. Participants A total of 350 intention-to-treat (ITT) patients aged 18 years or older with GORD of grade II and III were included in the study. The per-protocol (PP) population comprised 152 patients in the pantoprazole group and 136 in the pantoprazole plus cisapride group. Interventions Patients received either pantoprazole 40 mg once daily or pantoprazole 40 mg once daily plus cisapride 20 mg twice daily. Treatment outcome was assessed after 4 and 8 weeks. The primary criterion was endoscopically confirmed healing after 4 weeks. Additionally, relief of leading symptoms was studied. Main outcome measures The prior null hypothesis was no difference in healing rates between both treatment groups. Results After 4 weeks of treatment 81% and 82%, and after 8 weeks 89% and 90%, of PP patients treated with pantoprazole or pantoprazole plus cisapride were healed, respectively. Thus, equivalence of the two treatment strategies could be proven. Additionally, improvement of symptom relief showed no significant difference between the two regimens. In contrast to disease grade at baseline, Helicobacter pylori status did not influence the healing rates in our study. Both study medications were tolerated well. Conclusion Addition of cisapride to pantoprazole provides no further benefit in the treatment of GORD. © 2001 Lippincott Williams & Wilkins.
Description
Keywords
cisapride, pantoprazole, prokinetic agent, proton pump inhibitor, adult, article, clinical trial, controlled clinical trial, controlled study, disease severity, double blind procedure, drug efficacy, drug induced disease, drug tolerability, endoscopy, female, gastroesophageal reflux, healing, Helicobacter pylori, human, major clinical study, male, multicenter study, priority journal, randomized controlled trial, treatment outcome, 2-Pyridinylmethylsulfinylbenzimidazoles, Benzimidazoles, Cisapride, Double-Blind Method, Drug Therapy, Combination, Enzyme Inhibitors, Esophagoscopy, Female, Gastroesophageal Reflux, Gastrointestinal Agents, H(+)-K(+)-Exchanging ATPase, Humans, Male, Middle Aged, Omeprazole, Proton Pumps, Sulfoxides, Treatment Outcome
Citation
European Journal of Gastroenterology and Hepatology
13
8
13
8